REGISTER
Orforglipron Approved in China: First Oral GLP-1 Receptor Agonist for Weight Management
On November 12, 2026, the National Medical Products Administration of China approved Eli Lilly’s orforglipron calcium tablets, marketed as Muyouda, for long-term weight management in adults with obesity or overweight and a weight-related condition. Phase 3 ATTAIN data show a mean weight loss of 11.2% at 72 weeks with the 36 mg dose.

On November 12, 2026, the first oral GLP-1 receptor agonist for weight loss was approved for marketing in China, and the treatment of obesity is expected to enter a new phase. Around the topics of obesity management and scientific weight loss, MedJ asked experts in the field for their professional interpretation.

According to the National Medical Products Administration (NMPA), Eli Lilly Nederland B.V.’s orforglipron calcium tablets, marketed under the brand name Muyouda, have been approved as a Class 1 innovative drug for the long-term weight management of adults whose initial body mass index (BMI) is 30 kg/m² or above, or 27 kg/m² to below 30 kg/m² with at least one weight-related comorbidity, in addition to dietary control and increased exercise.

Previously, all GLP-1 receptor agonists approved for weight loss in China required subcutaneous injection. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist that needs to be taken once daily, with no restrictions on food or water intake.

“Chronic diseases still present many practical challenges in long-term management, and patients differ in how much they need, and in how much they accept, different routes of administration,” said Prof. Lixin Guo, the principal investigator for orforglipron in China at Beijing Hospital and the National Center for Geriatrics. “Against this background, oral GLP-1 receptor agonist regimens may further enrich the range of clinical treatment options.”

Article Key Points

• NMPA approved orforglipron on November 12, 2026, the first oral GLP-1 receptor agonist for weight management in China

• In ATTAIN-1, mean weight loss at 72 weeks was 11.2% with 36 mg orforglipron versus 2.1% with placebo

• In ATTAIN-2, the highest dose cut weight 9.6% versus 2.5% with placebo and lowered HbA1c by 1.8 percentage points

• Gastrointestinal adverse events were the main tolerability issue, with discontinuation for adverse events in 5.3-10.3%

• Access and cost remain decisive: oral semaglutide and orforglipron have set a demand benchmark in obesity care

Highest-Dose Group Lost an Average of 12.4 Kilograms of Body Weight

Obesity has become a global public health problem. Statistics show that between 1990 and 2021, the adult obesity rate worldwide more than doubled, and that in 2022 there were 880 million adults with obesity globally. In China, obesity ranks as the sixth leading cause of death and disability, with an adult obesity prevalence of 16.4% and an overweight rate of 34.3%.

Prof. Shen Qu, director of the Institute of Obesity at Tongji University, told MedJ: “For a long time, people did not think of obesity as a disease, and awareness of its harms was far from sufficient, until 1997, when the WHO defined obesity as a disease and society gradually began to recognise its long-term consequences.”

The arrival of GLP-1 receptor agonists has thoroughly rewritten the treatment of obesity and changed the way it is understood, as a chronic disease rooted in biology rather than a simple failure of willpower.

Dr. Hui Bi, associate chief physician of internal medicine at the Plastic Surgery Hospital of the Chinese Academy of Medical Sciences, told MedJ that these drugs have shown clear clinical value in controlling blood glucose, reducing body weight and improving fatty liver. “In patients with diabetes complicated by heart failure, cardio-cerebrovascular disease or chronic kidney disease, GLP-1 receptor agonists have also shown benefits in glycaemic control and weight loss, with gains in endpoint outcomes,”Dr. Bi said.

The problem, however, is that the penetration rate of GLP-1 receptor agonists remains low. Limited in part by the need for weekly injections, data show that penetration in type 2 diabetes is only 7%, and in obesity only about 1%, leaving substantial unmet clinical need and market potential. For this reason, developing an oral formulation has been seen as key to widening the treated population and improving adherence.

The approval of orforglipron was based mainly on the global phase 3 ATTAIN clinical programme, which enrolled more than 4,700 participants from China, the United States, Brazil, India, Japan and other countries. On a background of healthy diet and exercise, participants were randomly assigned to different doses of orforglipron or to placebo.

ATTAIN-1 enrolled 3,127 adults with obesity or overweight who did not have diabetes. At week 72, mean body weight had fallen by 7.5%, 8.4% and 11.2% in the 6 mg, 12 mg and 36 mg groups respectively, compared with 2.1% in the placebo group, showing a clear dose-dependent relationship.

When only the participants who remained on treatment were assessed, weight loss in the three dose groups reached 7.8%, 9.3% and 12.4%, compared with 0.9% in the placebo group. In the highest dose group, mean body weight fell by 12.4 kg, and about 40% of patients lost more than 15% of their body weight.

ATTAIN-2 enrolled 1,613 adults with obesity or overweight who had type 2 diabetes. At week 72, body weight fell by 9.6% in the highest dose group and by 2.5% in the placebo group; among participants who remained on treatment, weight loss in the highest dose group reached 10.5%, and glycated haemoglobin fell by 1.8 percentage points from a baseline of 8.1%, achieving both weight loss and glycaemic control.

Several metabolic markers improved at the same time as weight fell. In ATTAIN-1, non-HDL cholesterol, triglycerides and systolic blood pressure all decreased in the treatment groups, all of which are important risk factors for cardiovascular disease.

In terms of safety, orforglipron was broadly consistent with other GLP-1 receptor agonists. The most common adverse reactions were gastrointestinal, including nausea, constipation, diarrhoea and vomiting, mostly mild to moderate and concentrated in the dose-escalation phase. In ATTAIN-1, the proportion of patients in each dose group who discontinued because of adverse events ranged from 5.3% to 10.3%, compared with 2.7% in the placebo group.

A Large Unmet Clinical Need

Dr. Bi considers that the significance of an oral formulation lies first in adherence. She noted that among Chinese adults aged over 18, the proportion who are overweight or obese is close to half. Oral formulations are more readily accepted, whether the patient has obesity alone or has diabetes, cardio-cerebrovascular disease or chronic kidney disease.

This is particularly true for patients with simple obesity. “Some people are afraid to inject themselves in the abdomen or the arm. Now that there is an oral formulation, it is much more convenient to use,” Dr. Bi said.

In fact, oral weight-loss drugs have already shown substantial market demand.

Oral semaglutide was approved in the United States in December 2025. By the end of the third quarter of this year, cumulative prescriptions in the United States had exceeded 8 million, and third-quarter global sales reached about $810 million, which has been regarded as the fastest-ramping new product in the history of GLP-1 medicines in the United States. Orforglipron was launched in the United States in April, with first-quarter sales of $98 million.

What distinguishes orforglipron is that most earlier GLP-1 weight-loss drugs are peptides, which are easily degraded by digestive enzymes when taken orally and have difficulty crossing the intestinal wall into the bloodstream. Oral semaglutide addresses this by pairing the drug with an absorption enhancer, so that it is absorbed locally in the stomach. Because the absorption enhancer has to act locally around the tablet in the stomach, food and excess drinking water significantly interfere with absorption, so patients must take the drug on an empty stomach and cannot eat or drink more than 120 mL of water for 30 minutes after taking it.

Orforglipron, by contrast, is a small molecule. Small molecules themselves can be absorbed by the intestine and do not need an absorption enhancer, which means there is no restriction on fasting or on drinking water, and the drug can be taken at any time of day.

Worth noting is that, beyond innovation in route of administration, multi-target combinations are also becoming a competitive direction for weight-loss and glucose-lowering drugs.

On December 17, 2025, Nature published two clinical studies of Innovent’s mazdutide injection on the same day. Mazdutide acts on the GLP-1 and glucagon receptor dual targets, suppressing appetite while increasing fat consumption, and the studies showed better glycaemic control and weight loss than placebo or the specified comparator, with about 64% of patients losing more than 5% of body weight at 24 weeks.

Lilly’s GIP/GLP-1/GCG triple agonist is also in development. Phase 3 results showed an average weight loss of 28.3% over 80 weeks in the highest dose group, and the company plans to submit a marketing application to the US Food and Drug Administration in early 2027. In addition, because weight loss inevitably causes some loss of muscle mass, a new generation of drugs that reduce fat while preserving muscle is also being developed.

As the drugs are developed and iterated, clinical concepts are changing as well. In the past, weight-loss drugs were often regarded as a fallback option after lifestyle intervention had failed. Today, that order is being reconsidered.

According to the 2024 Chinese guideline for long-term weight management and the clinical use of anti-obesity drugs, for most patients who are overweight or obese, including those with abdominal obesity, and especially those who have failed to lose weight in the past or cannot maintain weight loss, weight-loss drug therapy can be started directly once the criteria for indication are met.

As lead author of that guideline, Prof. Shen Qu told MedJ: “This means that for patients with severe obesity and metabolic disorders, there is no need to wait until lifestyle intervention has failed before trying a weight-loss drug. What is advocated is that these patients start combination therapy early, intervene early and benefit early.”

In Dr. Bi’s view, more targets and more convenient administration also meet the pressing need for weight management today. “In 2024, the country launched the ‘Weight Management Year’ campaign, which shows that the whole society is placing increasing demands on ‘ weight management. Now, when prescribing, we are sometimes also asked to write long-term weight management’ on the prescription.”

She cautioned, however, that the stability and safety of any drug need time to be tested. Oral formulations may achieve better adherence and may be used in a broader population, and clinical practice must observe not only the efficacy of the drug but also monitor and manage its side effects.

0
0
Loading